{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095775","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.842431+00:00","generated_at":"2026-05-31T09:49:28.126158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Candel Therapeutics Q2 net loss $22.2M; cash runway into Q1 2025; positive CAN-2409 pancreatic data","bullets":["Net loss of $22.2M in Q2 2024 vs $9.6M in Q2 2023; includes $13.7M non-cash warrant liability adjustment.","Cash and cash equivalents $21.5M at June 30, 2024; expects funding operations into Q1 2025.","CAN-2409 in pancreatic cancer: median OS 28.8 months vs 12.5 months control; 24-month survival 71.4% vs 16.7%.","CAN-2409 in NSCLC: median OS 20.6 months in ICI-resistant patients; data presented at ASCO.","Orphan drug designation from FDA for CAN-2409 (pancreatic) and CAN-3110 (rHGG); phase 3 prostate data expected Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095775","json":"https://secwatch.observer/filing/0000950170-24-095775.json","markdown":"https://secwatch.observer/filing/0000950170-24-095775.md","text":"https://secwatch.observer/filing/0000950170-24-095775.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024095775/0000950170-24-095775-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024095775/cadl-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:49:28.126158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}